PKM and non-small cell lung carcinoma: Cisplatin-resistant NSCLC cells can be induced to secrete EVs in a hypoxic environment and transfer drug resistance to sensitive NSCLC cells via intercellular delivery of pyruvate kinase isozyme type M2 (PKM2) [95].